Operator
Good day, ladies and gentlemen and welcome to the Exelixis Fourth Quarter and Full Year 2020 Financial Results Conference Call. My name is, Latif, and I will be your operator for today. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to your host for today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. Please proceed.
Susan T. Hubbard
Executive Vice President, Public Affairs and Investor Relations
Thank you, Latif, and thank you all for joining us for the Exelixis fourth quarter and full year 2020 financial results conference call. Joining me on today s call are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; Gisela Schwab, our Chief Medical Officer; and P.J. Haley, our Executive Vice President of Commercial, who will together review our corporate, financial development and commercial progress for the fourth quarter 2020 ended December 31,
Search jobs 10-Jan-2021 Exelixis Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Financial Guidance, and Outlines Key Priorities and Anticipated Milestones For 2021
–
Cabozantinib Franchise Preliminary Net Product Revenue of $200 million for the Fourth Quarter 2020, and $741 million for the Full Year 2020 –
–
2021 Net Product Revenue Guidance of $950 million to $1,050 million –
– Corporate priorities for 2021 include potentially filing supplemental New Drug Applications for cabozantinib in three additional indications –
– Presentation and webcast at 2021 J.P. Morgan Healthcare Conference on Monday, January 11th at 5:20 PM EST / 2:20 PM PST –
ALAMEDA, Calif. (BUSINESS WIRE) Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2020, provided financial guidance for full year 2021, and delivered an updat